| 
		
		 WHO's 
		Kluge says European COVID-19 vaccine campaign is "unacceptably slow"
   Send a link to a friend 
		[April 01, 2021]  
		ZURICH (Reuters) - Europe's rollout of 
		vaccinations against COVID-19 is "unacceptably slow," the World Health 
		Organization's European head said on Thursday, raising concern that 
		delays in giving shots could prolong the pandemic as cases of variants 
		spread. | 
        
            | 
			
			 Only 10% of the region's population have received one vaccine dose, 
			and 4% have completed a full course, Hans Kluge said. 
 "The rollout of these vaccines is unacceptably slow," he said in a 
			statement. "... We must speed up the process by ramping up 
			manufacturing, reducing barriers to administering vaccines, and 
			using every single vial we have in stock, now."
 
 Europe was slower than Britain and the United States, not only to 
			order vaccines last year from companies but also in approving them. 
			Even once they were approved by the bloc, rates of vaccinations 
			there have largely trailed behind British and U.S. efforts.
 
			
			 
			Kluge said new infections in Europe were rising in every age group 
			except those aged over 80, a sign that the vaccinations that have 
			gone to older groups are working but that the stuttering rollout was 
			leaving younger people vulnerable.
 "As variants of concern continue to spread and strain on hospitals 
			grows, religious holidays are leading to increased mobility," the 
			WHO said in its statement.
 
			
            [to top of second column] | 
			
			 "Speeding up vaccination 
								rollout is crucial."
 In addition to tight supplies, squabbles over 
								exports and delays by some vaccine 
								manufacturers, and concerns over the safety of 
								the AstraZeneca/Oxford vaccine after rare 
								clotting events emerged have also curbed 
								vaccination momentum.
 
 Some countries are still not giving the 
								British-Swedish company's shots and others, 
								including Germany, are restricting them to 
								people over 60 years old.
 
 Regulators and the WHO have declared that the 
								shot's benefits outweigh risks and continue to 
								study the clotting incidents.
 
 (Reporting by John Miller; editing by Stephanie 
								Nebehay and John Stonestreet)
 
			[© 2021 Thomson Reuters. All rights 
				reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published, 
			broadcast, rewritten or redistributed.  
			Thompson Reuters is solely responsible for this content |